Hormone Clinical Trials

154 recruitingLast updated: May 21, 2026

There are 154 actively recruiting hormone clinical trials across 44 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Hormone Trials at a Glance

154 actively recruiting trials for hormone are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 2 with 43 trials, with the heaviest enrollment activity in Boston, Houston, and Seattle. Lead sponsors running hormone studies include Bayer, Emory University, and Fudan University.

About Hormone Clinical Trials

Looking for clinical trials for Hormone? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 154 trials

Recruiting
Phase 2

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center700 enrolled2 locationsNCT07340541
Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled536 locationsNCT06058377
Recruiting

A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer100 enrolled1 locationNCT06661122
Recruiting

An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia

Metastatic Hormonesensitive Prostate Cancer (mHSPC)
Bayer1,000 enrolled1 locationNCT07223372
Recruiting
Phase 2

Study of Screening Brain MRIs in Stage IV Breast Cancer

Triple-Negative Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute170 enrolled2 locationsNCT05115474
Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled302 locationsNCT07028853
Recruiting
Phase 3

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

Mild Traumatic Brain InjuryAdult Growth Hormone Deficiency
VA Office of Research and Development172 enrolled17 locationsNCT04867317
Recruiting
Not Applicable

Mobile Health for Adherence in Breast Cancer Patients

Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled506 locationsNCT06112613
Recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Metastatic Hormone Sensitive Prostate CancerNon-metastatic Castration-resistant Prostate Cancer
Bayer600 enrolled1 locationNCT06334120
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled1 locationNCT07137416
Recruiting
Phase 1Phase 2

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals181 enrolled25 locationsNCT07190300
Recruiting
Phase 1Phase 2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.92 enrolled12 locationsNCT07287917
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 3

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Growth Hormone Deficiency (GHD)
Lumos Pharma150 enrolled29 locationsNCT06948214
Recruiting
Phase 3

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.206 enrolled1 locationNCT07241416
Recruiting
Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Metastatic Hormone Sensitive Prostate CancerMetastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Janssen Cilag S.A.S.270 enrolled1 locationNCT07451002
Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled158 locationsNCT06982521
Recruiting
Phase 2

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Adult Growth Hormone DeficiencyGulf War Syndrome
Baylor College of Medicine20 enrolled2 locationsNCT05355272
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379